Qeios
December 9, 2025
Jacques Suspène, Sarah Huet, Sabine Berteina‐raboin et al.
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to prevent relapse. At the same time, psilocybin is increasingly being investigated for the treatment of various substance use disorders. This review aims to evaluate the results of the most recent clinical trials assessing psilocybin as a treatment for...
Preprints.org
October 17, 2025
Jacques Suspène, Sarah Huet, Sabine Berteina‐raboin et al.
preprint
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to prevent relapse. At the same time, psilocybin is increasingly being investigated for the treatment of various substance use disorder. This review aims to evaluate the results of the most recent clinical trials assessing psilocybin as a treatment for...
Pharmaceuticals (Basel, Switzerland)
December 28, 2022
Raphaël Serreau, Ammar Amirouche, Amine Benyamina et al.
13 citations
Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates to the compounds contained in various Psilocybe-type hallucinogenic mushrooms. It is difficult, however, to obtain and purify sufficient quantities of these compounds from fungi to carry out biological studies, hence the need to develop simple and...
Journal of Clinical Psychopharmacology
Ewen Kervadec, Aurore Bezo, Raphaël Serreau et al.
Ibogaine has garnered interest for its potential therapeutic properties in substance use and psychiatric disorders. Unlike classic psychedelics such as psilocybin or LSD, ibogaine remains underexplored in clinical research. This review aimed to synthesize the clinical literature on ibogaine use in humans over the past 3 decades, focusing on outcomes and safety. We conducted a narrative review...